ProPhase Labs, Inc. (PRPH)
-NasdaqGM 1.57 
0.01(0.63%) May 24, 4:00PM EDT
| Prev Close: | 1.58 |
|---|
| Open: | 1.58 |
|---|
| Bid: | 1.15 x 1000 |
|---|
| Ask: | 1.97 x 200 |
|---|
| 1y Target Est: | 15.55 |
|---|
| Beta: | 1.84 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.57 - 1.59 |
|---|
| 52wk Range: | 0.98 - 2.25 |
|---|
| Volume: | 3,780 |
|---|
| Avg Vol (3m): | 14,191 |
|---|
| Market Cap: | 24.88M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.01 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- PROPHASE LABS, INC. FinancialsEDGAR Online Financials(Tue, May 21)
- PROPHASE LABS, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security HoldersEDGAR Online(Tue, May 21)
- PROPHASE LABS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- PROPHASE LABS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote ofEDGAR Online(Thu, May 9)
- PROPHASE LABS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibEDGAR Online(Tue, May 7)
- ProPhase Labs Reports Financial Results for the First Quarter Ended March 31, 2013Marketwired(Mon, May 6)
- PROPHASE LABS, INC. Files SEC form 10-K, Annual ReportEDGAR Online(Thu, Mar 28)
- PROPHASE LABS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibEDGAR Online(Tue, Mar 26)
- ProPhase Labs Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012Marketwired(Tue, Mar 26)
- PROPHASE LABS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibEDGAR Online(Thu, Feb 28)
- PROPHASE LABS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Wed, Feb 6)
- 4 Merger and Acquisition Stock Stories To Draw Investor Interestat Wall St. Cheat Sheet(Tue, Feb 5)
- Matrixx Initiatives Withdraws Acquisition Offer for ProPhase LabsPR Newswire(Tue, Feb 5)
- Flu Epidemic Is Boon For Drugstore Chains Like Walgreens, Cough and Cold Marketersat Forbes(Mon, Jan 28)
- PROPHASE LABS, INC. Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online(Wed, Jan 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.05 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-10)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-10)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
ProPhase Labs, Inc. engages in the manufacture, marketing, and distribution of homeopathic and health products to the general public. It is also involved in the research and development of over-the-counter (OTC) drugs, natural base health products...
View More